Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | LCAT | P04180 | 1/20 | 0.40 |
| ▸ | XPO1 | O14980 | 10/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.34 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17537350 | 0.81 | MBOAT4 (0.41) | ADRB2MAPTNOTUMMBOAT4CNR2 | |
| SCHEMBL30562754 | 0.80 | ADRB2 (0.59) | ADRB2CXCR3LCATXPO1SLC6A9 | |
| SCHEMBL21905908 | 0.80 | ADRB2 (0.59) | ADRB2CXCR3LCATXPO1SLC6A9 | |
| SCHEMBL23779626 | 0.79 | ADRB2 (0.70) | ADRB2CXCR3LCATXPO1SLC6A9 | |
| SCHEMBL12780912 | 0.79 | ADRB2 (0.70) | ADRB2CXCR3LCATXPO1SLC6A9 | |
| SCHEMBL25390151 | 0.78 | ADRB2 (0.65) | ADRB2CXCR3LCATXPO1SLC6A9 | |
| SCHEMBL22489589 | 0.78 | ADRB2 (0.38) | ADRB2MAPTNOTUMMBOAT4CNR2 | |
| SCHEMBL29388809 | 0.76 | ADRB2 (0.97) | ADRB2CXCR3LCAT | |
| SCHEMBL12763838 | 0.76 | ADRB2 (0.67) | ADRB2CXCR3LCATSLC6A9SLC6A5 | |
| SCHEMBL906077 | 0.76 | ADRB2 (0.97) | ADRB2CXCR3LCAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4552697-A2 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2025-05-14 | — | — | EP | disclosed |
| EP-3514151-B1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| US-20240308979-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2024-09-19 | — | — | US | disclosed |
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2022-11-22 | — | — | US | disclosed |
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2022-11-22 | — | — | US | disclosed |
| US-20210387962-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2021-12-16 | — | — | US | disclosed |
| US-20210387962-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2021-12-16 | — | — | US | disclosed |
| CN-113214246-A | Protein kinase C inhibitors and methods of their use | 诺华股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-11059804-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2021-07-13 | — | — | US | disclosed |
| US-11059804-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2021-07-13 | — | — | US | disclosed |
| US-20160347737-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-20160347737-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-12-01 | — | — | US | disclosed |
| US-9452998-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-9452998-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-9452998-B2 | Protein kinase C inhibitors and methods of their use | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20160046605-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-02-18 | — | — | US | disclosed |
| US-20160046605-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-02-18 | — | — | US | disclosed |
| US-20160046605-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-02-18 | — | — | US | disclosed |
| WO-2016020864-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016020864-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308979-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | ADRB2 3686/4885CXCR3 2449/4885LCAT 954/4885 |
| US-20210387962-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | ADRB2 3686/4885CXCR3 2449/4885LCAT 954/4885 |
| US-11505541-B2 | Protein kinase C inhibitors and methods of their use | PRKCA, PRKCB, PRKCH | ADRB2 3686/4885CXCR3 2449/4885LCAT 954/4885 |
| US-20160046605-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | ADRB2 3686/4885CXCR3 2449/4885LCAT 954/4885 |
| US-11059804-B2 | Protein kinase C inhibitors and methods of their use | PRKCA, PRKCB, PRKCH | ADRB2 3686/4885CXCR3 2449/4885LCAT 954/4885 |
| US-20160347737-A1 | PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE | PRKCA, PRKCB, PRKCH | ADRB2 3686/4885CXCR3 2449/4885LCAT 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.